Urethral syndrome: response to alpha-adrenergic blocking agents.
Urethral syndrome patients have irritative bladder symptoms in the absence of any objective urological findings. While not life threatening, it can have a severe disruptive effect on the quality of life. Attempts at symptom control are not always effective because of lack of clarity about the underlying aetiology. We describe a case of a 27-year-old patient whose irritative bladder symptoms showed response to alpha-adrenergic blocking agents on two separate occasions during the course of her treatment.
Sinha
Deepali
D
Obstetrics and Gynaecology, City Hospital, Birmingham B18 7QH, UK. adsinha@hotmail.com
Arunkalaivanan
A
A
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D003863:Depression / Q000139:chemically induced; D005260:Female; D006801:Humans; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D013449:Sulfonamides / Q000627:therapeutic use*; D013577:Syndrome; D000077409:Tamsulosin; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D013449:Sulfonamides; C047638:alfuzosin; D000077409:Tamsulosin